Form 4 for WVE Wave Life Sciences, Inc.
Accepted 2024-10-01 00:00:00 ET · period of report 2024-09-27 · accession 0001999371-24-012789 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2024-10-01 | 2024-09-27 | WVE | GSK plc | 10% | P - Purchase | $8.00 | +2.79M | 16.78M | +20% | +$22.34M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2024-09-27 | P | A | 2,791,930 | $8.00 | 16,775,691 | I By Corporation | — | — | (F1) The shares reported herein are held of record by Glaxo Group Limited, a wholly-owned subsidiary of GSK plc (the "Reporting Person"). |